PPM1D and hematologic disorder: Since truncating mutations in PPM1D were identified in patients suffering from therapy-related hematological disorders [28, 29], we employed our previously established Ppm1dT/+ mouse model [27] to investigate the impact of this gain-of-function allele on hematopoiesis (Supplimentary Fig. 1A).